click company/industri name report summari
new strategi offer promis like take time assum coverag
hold rate price target
upgrad buy ahead aducanumab upcom regulatori saga pt
price estim chang
despit higher oper expens long-term thesi intact reiter buy
hcm outlook posit sever key catalyst approach buy pt
tusker acquisit add strong long-term asset ent portfolio maintain
aerospac defens
biomed devic servic
what med-tech dive earn ndr trade show
biomed devic servic
nan like direct neuromodul field
recap focu stock
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif
public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object
view design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author
fca report european issuer non-independ research market commun market abus regul fca
conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect analyst person independ object view
design invest relev issuer discuss herein
import inform pleas see import disclosur begin page document
back index
new strategi offer promis like take time
assum coverag hold rate price target
assum coverag hold rate previou rate
buy view reflect new strateg vision balanc risk
divestitur near-term market pressur form us/china trade tension
believ transit away commod product line
non-cor busi ultim bear fruit recogn benefit like
take time fulli realiz
somewhat concern near-term macro pressur us/china trade
tension remain headwind compani weigh top- bottom-
given concern choos assum coverag sidelin
look becom construct share sign emerg
streamlin effort believ like come
new price target base upon new ep estim
buy
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
hold
upgrad buy ahead aducanumab upcom
regulatori saga pt
skeptic remain see upsid head adu battl
surpris anyon sudden reviv aducanumab adu
short earli alzheim diseas see addit retain healthi degre
skeptic around trial data present ctad meet see
believ skeptic gener share perhap warrant sever
expert interact ctad investor said also note mani
skeptic appear agre aducanumab varieti reason
decent shot fda approv view reflect share current level
mind like opportun present head regulatori
saga aducanumab upgrad buy acknowledg
risk along way see stock call base less opinion around
merit lack thereof science/data and/or long-term implic
eventu regulatori outcom adu howev underestim investor fear
miss potenti get ahead might approv first
ever disease-alt therapi alzheim simultan present high unmet
need larg address market
valuat remain favor price-to-earnings vs consensu
larg cap biooharma peer mani pay dividend unlik manag
estim financi flexibl mean could buy growth
get less gun shi later-stage/commercial-focus acquisit also believ
investor model credit littl valu ex-adu pipelin
pipelin still target rel high-risk/high-reward indic note
sever readout come see tabl separ like growth
especi ex-u biosimilar could drive longer term
risk exist around tecfidera multipl sclerosi spinraza sma
report expect anoth decent quarter near term
see key ex-adu risk well rule inter part review ipr
tecfidera patent expir come earli convent paragraph
iv gener challeng exist well see tecfidera largest product
revenu note success defend ipr
patent ipr result broken patent lead
quick gener launch convent p-iv challeng note gener financi
capac launch risk significantli curtail given current pressur part
industri spinraza spinal muscular atrophi watch develop
novarti zolgensma gene therapi intrathec deliveri file could later year
potenti depend partial clinic hold statu roche/ptct oral risdiplam
action date still view spinraza first approv product type
sma potenti longer tail investor current give credit
rais pt mainli higher probabl adu approv
ad quarter model among tweak revenu
ep respect consensu
may basi key chang lead higher
price target vs previous probabl approv adu
vs discount back end vs page dcf
scenario around aducanumab vari probabl approv vs base case
tecfidera gener entri model base case
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
intact reiter buy pt
manag introduc ran market growth assumpt
reiter compound-annual-growth-rate believ ericsson potenti gain market
share grow faster market growth assumpt complet
restructur program improv margin digit servic manag
servic believ ericsson solid foundat continu margin expans
remain track achiev oper margin target
recent eu cybersecur report singl china threat follow
huawei allow franc germani telefonica select huawei along
nokia believ ericsson potenti solid share china contract
beyond lte share believ manag success stabil
busi made necessari chang compani invest cycl
reiter buy rate target price
network oper margin weigh result larg maintain estim
reiter pt ericsson report result in-lin revenu lower
expect oper margin driven network impact kathrein expens
continu invest corpor project digit complianc
secur network north american revenu soft due headwind t-
mobile/sprint merger uncertainti off-set strength middl
east north east asia gross margin line consensu
estim manag highlight solid network gross margin despit
weaker sale mix typic higher margin north american market
base result manag plan assumpt guidanc maintain
target total group net sale estim larg maintain
versu sek previous reflect continu strong
momentum market growth model sequenti growth
better normal season due reflect weaker north american
result follow solid network gross margin resili off-set continu near-
term gross margin headwind strateg contract network larg china
deploy well guidanc slightli higher oper expens due
invest complianc kathrein secur digit slightli decreas
oper margin assumpt overal
non-ifr ep estim decreas slightli
result us maintain target price base roughli
target remain track ericsson contract live
network manag expect ran market growth continu
ramp global believ ericsson win market share nokia driven
strength softwar dss offer gain traction custom nokia
struggl softwar cost structur issu recent investor updat call
manag increas target highlight progress across
group sinc target set includ top-lin return growth margin
expans strong execut revenu target increas updat
call reflect stronger market develop kathrein acquisit growth
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
hcm outlook posit sever key catalyst
sever major catalyst way hcm surufatinib savolitinib
fruquintinib believ current share under-valued provid opportun
buyer
first wholly-own oncolog product surufatinib like launch
string highli posit outcom sanet-ep sanet-p trial lead
earli complet studi china met endpoint earli look forward
see product potenti launch initi patient extrapancreat
neuroendocrin tumor remain optimist similar data us/eu surufatinib
neuroendocrin tumor trial initi would posit especi given high
unmet need indic furthermor expect chines surufatinib phase interim
data patient second line biliari tract cancer thu far surufatinib
shown highli encourag data neuroendocrin tumor china await us/eu
data valid product
sever data readout savolitinib
shape busi year savolitinib get sever key us china
readout us phase savoir studi papillari rcc phase interim
savolitinib tagrisso combin savannah studi nsclc may present data
respect savannah studi focus patient met egfrm
nsclc progress follow tagrisso egfr-tki base shown
tatton similar popul savolitinib tagrisso combin demonstr
orr month posit given advanc diseas
popul addit see chines phase data savolitinib nsclc
patient
phase interim data readout fruquintinib gastric cancer
fruquintinib current market china third later line colorect cancer
studi product continu proceed one trial phase frutiga
studi investig use fruquintinib taxol second line gastric cancer patient
expect interim readout
maintain buy rate price target encourag compani
recent string posit data surufatinib neuroendocrin tumor believ
signific posit could hold addit upsid replic us studi
furthermor think result tatton studi support potenti posit
readout futur savannah trial readout believ hcm share under-valued
current level would buyer
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
biomed devic servic
tusker acquisit add strong long-term asset
maintain buy rate follow announc snn acquir tusker
medic privat med-tech compani focu ent space specif
in-offic solut placement tympanostomi tube commonli refer
ear tube term deal disclos snn histori
predictor rotat medic ceterix expect structur includ
up-front execution-bas mileston payment view acquisit highli
complementari snn ent portfolio find encourag new ceo roland
diggelmann keep foot ga pedal despit helm
month net net continu think snn share offer attract risk/
reward current level though note return sinc decemb
somewhat dampen enthusiasm regard near-term risk/reward setup
share current trade ep nevertheless advis investor
use share weak come month build posit ahead
think prolong period execut market share gain support
comprehens differenti product portfolio maintain buy rate
addit detail tusker medic develop tula system in-offic solut
tympanostomi tube also known ear tube use treat recurr persist
ear infect young children tula system receiv fda pma approv
via breakthrough devic pathway elimin need gener anesthesia
tympanostomi procedur enabl tube place safe effect
physician offic view novel aspect tula system iontophoresi
compon enabl local anesthesia deliv effici eardrum
surround tissu technolog also includ tube deliveri system use
awake/alert young patient statist cdc suggest children receiv
procedur year tusker websit state procedur
annual technolog certainli new office-bas reimburs pathway
need develop view signific long-term opportun smith
 nephew given strengthen exist ent franchis snn note plan begin
commerci launch later look forward addit commentari
commerci plan result call februari
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
today cdc publish weekli flu surveil report week end
jan report detail percentag outpati visit us attribut
influenza-lik ill ili provid gener medic telehealth visit
treat patient ili sever flu season directli impact visit volum
week outpati visit ili
week show revers declin flu season saw first two week
year week outpati visit due ili symptom
increas last week still averag
week common see downtick flu week
year resurg sever week follow last year flu season
peak week year week week
week pre-releas better-than-expect result part
due flu continu monitor flu next sever month gaug
impact
flu season impact
compani core busi provid low-acu gener medic telemedicin visit
base manag previou comment averag month
gener medic visit come patient experienc ili symptom
winter month expect near high end rang sever flu
season manag indic could exceed rang sever flu
season would impli greater volum
diversifi busi last year acquisit best
doctor expert second opinion acquisit advanc medic diversifi
intern provid expans behavior health offer thu flu
impact less meaning rel basi vs past year
past commentari flu
flu season flu season got slow start follow modest
lift late overal saw flu visit declin
flu season earn call management state flu season
moder compar worst flu season sinc
line year also management state
flu smaller rel impact overal volum given compani
diversif new servic offer management indic achiev low
high end guidanc would larg influenc sever flu
flu season flu season worst record sinc
season notabl peak earli earn call
manag said compani conduct visit per day
visit due ili compani also note januari gener
medic visit new user import mani new user
like use servic within year earn call
manag note saw increas project util
strong flu season januari februari
valuat recogn current stock price reach price target
intend reevalu price target near term
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
aerospac defens
back index
aerospac defens
price close busi januari
complet commerci aerospac survey outlook
result better expect believ on-going max
ground continu place premium current aircraft continu gradual
support higher spend level increasingli less concern surg
retir unground base expect prolong rt process
drop aftermarket growth due challeng comp yet materi
fact outlook sale growth increas last survey
continu recommend commerci exposur
industri remain gener conserv extent max
ground impact commerci exampl approxim
respond expect ground increas demand ultim impact
uncertain howev close indic ground would either impact
busi would net neg due impact ip sale
continu believ product ramp unground
slower expect believ continu tailwind longer
expect
gener bullish commerci aftermarket result
survey indic sale part purchas sequenti
survey howev consid fact sale came still
slight discrep part purchas view posit quarter
engin segment strongest term part purchas actual sale
held back tight engin capac europ show surpris strength part
price remain elev backlog growth moreov tight
labor market seem help mro improv labor rate quarter
outlook full-year improv bp specif mro
look growth survey outlook
compon engin held steadi heavi line segment saw
improv believ fundament engin market remain strong
capac constraint limit near-term upsid moreov increas
spend older engin neg impact avail materi
on-go teeth issu new engin also soak capac howev next
six-month outlook cautiou could point slow start
total commerci transport retir aircraft
repres increas still well averag
wide-bodi aircraft account much increas narrow-
bodi retir note much increas legaci
mcdac aircraft account increas expect on-go replac
retir possibl see surg retir result
rt
defens stock outperform aerospac stock far
believ sentiment commerci oe supplier improv news
flow improv get boost start deliv airplan
moreov believ re-start product line posit
suppli chain howev believ full financi impact ground yet
reflect estim mani supplier commerci exposur
continu recommend
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
biomed devic servic
price close busi januari
what med-tech dive earn ndr
trade show
bottom line come nan publish separ note concurr
today well echo commentari med-tech-a-palooza note publish
earlier last week see note neuromodul space burst seam
innov think nevro pdn data present past
weekend outstand also neuromod product target mani diseas
state oab movement disord ra etc look week ahead ew print
thursday like ew pullback via competitor call last week regard weaker
decemb tavr trend check suggest might well holiday-rel nois
think off-set strong start within think
ew gener tavr result could meet exceed street target also upcom
week host buy-rat ndr look forward get updat
thought regard time fda panel oc heart well progress
oc heart dcd trial full-servic model
earn page follow preview coverag name print result
week includ buy pt ew buy
event host transmed buy pt ndr minneapoli
boston wednesday januari thursday januari respect
recent trade trend med-tech
large-cap med-tech market cap trade wk/wk price-to-earnings vs
multipl last week group continu trade high end multi-
decad peak/trough level exclud depth financi crise rel
year respect
mid-cap med-tech market cap valuat also trade slightli wk/wk
end week price-to-earnings multipl vs multipl last week mid-cap
current trade midpoint histor peak/trough rang
small-cap med-tech market cap trade flat wk/wk ev/
sale median multipl group current trade midpoint multi-decad
peak/trough rang respect rel year note small-
cap group achiev all-tim peak multipl septemb prior
peak peak achiev multipl occas
point med-tech group multipl broke new high
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
biomed devic servic
price close busi januari
nan like direct
neuromodul field whole
bottom line nan repres omnia come parti also seem
steal show stellar pdn data think omnia first potenti
notabl splash revenu model could seen earli beyond
commercial-focus updat illustr industri increas
focu person therapi patient albeit updat immin new product
pipelin seem us iter natur vs novel product advanc
possibl except could mdt/stimgen albeit think earli tell
inde mdt recent acquisit stimgen dtm waveform provid firm
novel waveform coupl solid three-month data present nan could
give competit edg next quarter vs
view said didnt get strong sens physician meet
convinc dtm waveform materi better lead us believ long-term follow-
data month necessari prove inde better/differ
think omnia give compel competit proposit
abl offer broadest multi-mod option given nvro exclus high
frequenc also impress differenti uniqu
nalu neurostimul system power technolog check
suggest could market expand long-term beyond remain bullish
prospect saluda medic evok system expect full us launch
lastli think stimwav could turnaround stori watch
progress think inde larger role wireless pn within
takeaway thought
redefin market expand scss capabl priorit clinic
data nvro entranc us market half decad ago firm novel
therapi challeng larg sleepi field wake mani way drive
innov mani facet technolog includ program option
person therapi new innovation/product includ subsequ
year latter launch drove acceler market growth submit
two key takeaway wake-up call field place higher
prioriti better substant clinic evid rct data rather
market taglin good ole buddi relationship engin advances/
innov expand applic beyond sole leg pain similarli look
futur think industri dedic sponsor clinic studi new
area like pdn non-surg back uln among other bode well market
growth could materi impact share within space within specialti
place higher premium scienc clinic outcom think success
clinic trial like nvro pdn trial also portend posit insur coverag
decis promulg higher util among physician
higher-qu clinic data could advantag posit therapi earlier
pain manag continuum reduc countri opioid util
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
price close busi januari
recap focu stock
week ago saw flurri news note provid summari
import news relat cover compani addit highlight notabl
meet week item note
highlight focu stock
hiiq pre-announc result
updat estim follow hiiq
rais pt bio
lower pt hiiq
addit provid thought primari care digit therapeut
sector met number innov privately-held compani
teladoc rais pt rais forecast incorpor strong
preliminari guidanc new pt includ intouch acquisit announc
model wait transact close
rais pt compani discuss result
announc extend expand nation contract aetna
high confid achiev annual synergi
livongo livongo provid posit updat start
announc partnership partnership demonstr cgm
complimentari servic subscription-bas health coach servic livongo
provid thu investor concern mitig
evol rais pt report posit news ky medicaid
rfp preliminari servic guidanc updat model accordingli
allscript updat model reflect recent debt deal
preliminari guidanc book upsid revenu shortfal
hm hold updat model reflect accent acquisit close
insur innov lower pt updat
model reflect weak guidanc provid lower estim
reflect lower level growth medicar busi
castlight met new ceo cfo impress new
manag team chang implement remain sidelin
given potenti churn come quarter
met ceo newli hire president/coo impress
given prior background presid optum analyt
primari care practic manag primari care evolv disrupt
tradit model pendulum swing away hospital-employ primari care
met privia health villagemd paladina health firefli health galileo
digit therapeut dtx nascent dtx industri tri set foundat
growth met industri leader click therapeut
omada health fit squar primari care digit therapeut omada
whose busi model resembl livongo yet higher touch servic model omada
also integr abbott view offer complimentari
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
back index
price close busi januari
amazon think amazon decis offer one-day ship prime member
valid acceler on-line store revenu unit growth throughout
howev compani spend heavili expand program
investor like look better sens long invest cycl
last expect y/i total revenu growth amazon deliv mid-
teen on-line store revenu growth continu expand advertis busi
forecast y/i contract oper margin relat
billion invest expand one-day ship program aw anoth segment
investor tend keep close eye estim y/i revenu growth
oper margin margin improv
headwind relat implement on-line sale tax sever
remain state includ california texa like continu neg
impact us marketplac gmv result anticip y/i declin
total gmv quarter lead declin overal revenu despit
stabl user trend novemb announc sale stubhub busi
european competitor viagogo billion transact expect
close expect learn plan around classifi last
major piec remain compani on-going strateg review follow
complet strateg review process think investor shift focu
faster grow payment advertis busi scale compani
think advertis busi gener billion annual revenu
manag payment busi gener billion revenu million
facebook expect facebook report anoth quarter stabl user trend
global mau growth y/i look commentari compani
initi drive increas engag core platform watch
group date see advertis revenu growth y/i
deceler partial relat anticip privacy-rel headwind
recent note digit advertis trend expert call highlight
progress stori ad see increas adopt advertis
due combin factor still price discount news feed ad
gap like close time addit wsj recent report
facebook reconsid decis introduc ad whatsapp
compani strategi potenti shift focu commun
becom increasingli popular app billon mau around
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ
object view compani secur subject report discuss herein
